We are live on ! Find out more
FSTX

F-star Therapeutics, Inc. Common Stock
FSTX

Delisted

FSTX was delisted on the 8th of March, 2023.

Back to rankings

0 hedge funds and large institutions have $0 invested in F-star Therapeutics, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 59 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 59 → 0 (-59)

100% less funds holding in top 10

Funds holding in top 10: 2 → 0 (-2)

100% less capital invested

Capital invested by funds: $57.8M → $0 (-$57.8M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 59

Holders
–
Holders Change
-59
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
59
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$6.32M
2
RSCM
Rock Springs Capital Management
Maryland
-$4.75M
3
TC
Trium Capital
United Kingdom
-$4.3M
4
AVLSA
Atlas Venture Life Science Advisors
Massachusetts
-$3.79M
5
DCM
DAFNA Capital Management
California
-$3.65M
Name Holding Trade Value Shares
Change 		Change in
Stake
T. Rowe Price Associates
26
T. Rowe Price Associates
Maryland
– -$398K -63,047 Closed
PCM
27
Prelude Capital Management
New York
– -$384K -60,807 Closed
TI
28
Tidal Investments
Wisconsin
– -$350K -55,400 Closed
FAM
29
Formidable Asset Management
Ohio
– -$350K -55,366 Closed
Susquehanna International Group
30
Susquehanna International Group
Pennsylvania
– -$348K -55,066 Closed
TA
31
TLS Advisors
Florida
– -$343K -54,298 Closed
Bank of New York Mellon
32
Bank of New York Mellon
New York
– -$336K -53,122 Closed
STC
33
Sarah T. Connolly
– -$335K -53,001 Closed
RCI
34
Ridgeback Capital Investments
Florida
– -$332K -52,509 Closed
WAM
35
Wolverine Asset Management
Illinois
– -$323K -51,101 Closed
BC
36
Brookfield Corp
Ontario, Canada
– -$316K -50,000 Closed
FFH
37
Fairfax Financial Holdings
Ontario, Canada
– -$312K -49,399 Closed
Man Group
38
Man Group
United Kingdom
– -$268K -42,411 Closed
Northern Trust
39
Northern Trust
Illinois
– -$222K -35,102 Closed
SC
40
Shay Capital
New York
– -$148K -23,456 Closed
PCM
41
PenderFund Capital Management
British Columbia, Canada
– -$195K -22,760 Closed
Millennium Management
42
Millennium Management
New York
– -$118K -18,645 Closed
Squarepoint
43
Squarepoint
New York
– -$94.1K -14,888 Closed
HHGC
44
Hunting Hill Global Capital
New York
– -$93.3K -14,767 Closed
VF
45
Virtu Financial
New York
– -$88K -13,933 Closed
Charles Schwab
46
Charles Schwab
California
– -$85.9K -13,596 Closed
PCA
47
Private Capital Advisors
Connecticut
– -$83K -13,083 Closed
SAM
48
Silvercrest Asset Management
New York
– -$79.5K -12,585 Closed
Envestnet Asset Management
49
Envestnet Asset Management
Illinois
– -$69.9K -11,067 Closed
WSFS
50
Wilmington Savings Fund Society
Delaware
– -$63K -10,000 Closed
1
2
3

FSTX Hedge Fund Activity: Q1 2023 in Review

0 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in F-star Therapeutics, Inc. Common Stock (FSTX) for Q1 2023, worth a combined $0 — down 100% from $57.8M a quarter earlier.

Sellers outnumbered buyers: 59 funds closed out of FSTX and 0 opened new positions — a net loss of 59 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Armistice Capital, exiting entirely with an estimated $6.32M sold.

  • 0 institutional investors held F-star Therapeutics, Inc. Common Stock (FSTX) as of Q1 2023, down from 59 in Q4 2022.
  • Funds reported $0 of F-star Therapeutics, Inc. Common Stock stock for Q1 2023, down 100% quarter-over-quarter.
  • 0 funds opened new F-star Therapeutics, Inc. Common Stock positions in Q1 2023 and 59 closed out, a net change of -59 holders.
  • The largest F-star Therapeutics, Inc. Common Stock seller in Q1 2023 was Armistice Capital, an estimated $6.32M sold.

Based on aggregated 13F filings for Q1 2023.